Thyro-Tabs Articles

Abbott ups forecast on better-than-expected third quarter results

15 October 2009

53% jump in 1st-qtr profit for Abbott

15 April 2009

Harmful drug-drug interactions for thyroid medicines identified

15 September 2008

Revised monograph for levothyroxine to be issued in USA

4 August 2008

FDA moves to ensure thyroid drug potency

15 October 2007

Abbott Labs' 3rd-qtr earnings up 5.2% to $716M, on 52% Humira sales hike

30 October 2006

USA

22 August 2005

Abbott Labs delivers 1st-qtr 2005 double-digit growth on comparable basis

18 April 2005

Abbott Labs sees double digit 4th-qtr growth, fuelled by Rx drugs

24 January 2005

FDA rates Lannett's levothyroxine AB

20 December 2004

King's 3rd-qtr profit plunges, may restate

8 November 2004

US uninsured "pay 78% more than best Rx prices"

1 November 2004

Abbott posts 10.2% sales growth for 3rd-qtr 2004, led by arthritis drug Humira

25 October 2004

KV resolves a handful of legal matters

20 September 2004

Experts warn on levothyroxine potency differences

16 August 2004

King's 2nd-qtr net loss rockets 81%

16 August 2004

Stock Commentary - New York

5 July 2004

US drug import task force hears mostly negative views, many from pharma

26 April 2004

Abbott sees 13.9% rise in sales for 1st-qtr 2004

19 April 2004

Second FDA drug imports "blitz" finds 80% come from Canada

9 February 2004

US market developments in 2002-3 and the rise of generics; CBI meeting

8 December 2003

US FDA/Customs import blitz finds 88% contained unapproved drugs

6 October 2003

Stock Commentary - New York

12 May 2003

King gets Orange Book patent for Levoxyl

5 May 2003

Stock Commentary - New York

5 August 2002

King Pharma posts 36% leap in earnings

5 August 2002

Abbott's Synthroid FDA approved

5 August 2002

Abbott to get Synthroid approval by August?

22 July 2002

King 2003 guidance predicts EPS of $1.66

8 July 2002

King Pharma predicts EPS of $1.66 in 2003

8 July 2002

Multiple-inflation rate price rises claimed for US seniors' most-used Rx drugs

8 July 2002

Stock Commentary - New York

1 July 2002

King Pharma has 20 Levoxyl patents pending

1 July 2002

Mylan Labs receives FDA approval for hyperthyroidism drug

17 June 2002

Abbott Labs posts strong 1st-qtr sales and earnings growth

22 April 2002

Abbott posts strong revenue growth for 2001, but charges hit

21 January 2002

Abbott sales up 26% though earnings slip

11 October 2001

Abbott sales up 26% though earnings slip

10 October 2001

Abbott files NDA for Synthroid

2 August 2001

King Pharmaceuticals 2nd-qtr earnings leap 77%

25 July 2001

Judge rules in favor of Abbott over Watson in Synthroid case

23 July 2001

FDA orders cutback on Synthroid distribution

16 July 2001

Abbott sales growth driven by pharma

13 July 2001

Abbott sues Watson on misleading info regarding Synthroid

18 June 2001

US seniors' Rx cost rises "are double inflation"

15 June 2001

Abbott challenged by Gray Panthers

5 June 2001

Synthroid may be removed from market

1 June 2001

FDA approves King's Levoxyl

30 May 2001

US consumer groups pledge more lawsuits

15 May 2001

Abbott to file NDA for Synthroid

3 May 2001

King Pharma profits more than double, driven by Altace

21 February 2001

Watson launches four new products

15 January 2001

BASF sells pharma business to Abbott Labs for $6.9 billion in cash

15 December 2000

BASF excited about prospects for D2E7, as rumor mill talks of pharma

15 November 2000

Shareholders approve merger of King Pharmaceuticals and Jones Pharma

4 September 2000

First levothyroxine NDA backed by FDA

25 August 2000

Knoll gets approval for Synthroid settlement

10 August 2000

BASF reports hugely successful 2nd qtr, with net income up 322.6%

8 August 2000

King Pharmaceuticals merging with Jones Pharma in $3.4 billion deal

14 July 2000

US doctors wrote 9% more scripts last year

25 April 2000

BASF sets ambitious growth targets for 2000-2002, after positive 1999 trends

16 March 2000

Boots and BASF accused in Canada

29 February 2000

BASF holding onto pharma unit though pressure on for higher profit returns

15 February 2000

BASF Pharma hoping to catch up with top pharmaceutical companies

23 September 1999

BASF Pharma first-half sales up 9% and speeding up

21 September 1999

BASF sees profits collapse as earnings are hit by vitamin price-fixing

6 August 1999

No wrongdoing by Knoll in Synthroid case

2 August 1999

Knoll agrees to pharmacy grant

22 July 1999

Third-party payers lead Rx payments

5 May 1999

BASF Pharma on lookout for partner?

3 February 1999

US Seniors "Pay Up To 1,407% More For Rx Drugs"

29 September 1998

Knoll To Comarket Genzyme's Thyrogen

21 August 1998

USA's Most-Dispensed Rx Drugs In April 1998

20 May 1998

BASF Not Looking To Sell Pharma Business

30 March 1998

BASF Profits Up But Pharma Growth Down

14 November 1997

Knoll To Settle Synthroid Lawsuit

22 August 1997

BASF/Knoll Faces Lawsuit In USA Over Synthroid

26 May 1997

Generic And Branded Thyroid Drugs "Equal"

23 April 1997

Levothroid Batches Recalled In Spain

17 June 1996

Premarin Heads Top-10 Prescription Drugs

1 April 1996

Boots Deal Strengthens Pharma At BASF

17 April 1995

BASF Pharma Sales Slip In 1994 Hit By Currencies

17 April 1995

Good Half-year For Boots But No News On Pharma

7 November 1994

Roberts Acquires Product Licenses

26 September 1994

BOOTS LOOKING MORE TO THE OTC SECTOR

13 June 1994

BOOTS HOPES TO SWAY CITY WITH RESULTS

7 June 1993

RECORD RESULTS FOR FOREST LABS

8 February 1993

ANALYST'S ESTIMATES OF US THIRD QTR EARNINGS

12 October 1992

SMALLER US COMPANIES POST GOOD RESULTS

18 May 1992

Showing 1-89 of 89 articles

Go to beginningPrevious
  • 1
NextGo to end